Currently Viewing:
American Society of Clinical Oncology Annual Meeting
Currently Reading
Dr Sara M. Tolaney on Challenges With Treating, Role of Clinical Trials in HER2-Positive Breast Cancer
August 08, 2018
Dr Dennis P. Scanlon Explains Costs Associated With the Opioid Epidemic
July 27, 2018
Dr Michael Thompson Outlines Challenges With the Mass Adoption of EHRs, Precision Medicine
July 25, 2018
Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast Cancer
July 23, 2018
Dr Peter Paul Yu Explains Current Challenges With Precision Medicine
July 18, 2018
Where Dr Victoria Villaflor Thinks the Future of Precision Medicine Is Headed
July 08, 2018
Dr Peter Paul Yu on Progress in the Move Toward Interoperability
July 06, 2018
Dr Michael Thompson on Conducting Precision Medicine Trials in the Community Setting
July 05, 2018
Leonard Saltz: Novel Approaches to Colon Cancer, Behaviors That Impact Survival
July 02, 2018
Dr Sara M. Tolaney: Standard of Care, Novel Approaches for Treatment of HER2-Positive Breast Cancer
June 28, 2018
Dr Victoria Villaflor Discusses How Novel Therapies Have Changed Cancer Treatment
June 26, 2018
Dr Peter Paul Yu: How Next-Generation Sequencing is Changing Cancer Care
June 21, 2018
Dr James Lin Chen on the Shift to Precision Medicine
June 18, 2018
Ellen Miller Sonet: The Importance of Cancer Care Providers Informing Patients of Treatment Costs
June 17, 2018
Dr Michael Thompson Highlights Novel Therapies Being Used in Hematologic Malignancies
June 16, 2018
Dr Leonard B. Saltz: The Role of Next-Generation Sequencing in Advancing Precision Medicine
June 14, 2018
Study Underscores Value of PROs in Improving Lung Cancer Survival
June 07, 2018
Discussing the Cost Burden of Cancer With Patients
June 06, 2018
Managing Cancer-Related Pain in the Era of the Opioid Crisis
June 06, 2018

Dr Sara M. Tolaney on Challenges With Treating, Role of Clinical Trials in HER2-Positive Breast Cancer

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses challenges with managing patients with HER2-positive breast cancer and how clinical trials provide another treatment approach for these patients.


Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses challenges with managing patients with HER2-positive breast cancer and how clinical trials provide another treatment approach for these patients.

Transcript

What challenges are there in the management of patients with HER2-positive breast cancer?

I think one particular challenge for patients with HER2-positive disease, unfortunately, is brain metastases. Approximately hald of all patients who develop metastatic HER2-positive disease will die from progression in the brain, and so, there have been much efforts made to try to improve outcomes for these patients. One class of drugs that we’ve focused on for this patient population has been the use of tyrosine kinase inhibitors. These agents have a lower molecular weight than monoclonal antibodies and are able to penetrate through the blood-brain barrier.

There have been several trials done looking at these agents, and a few trials would suggest that when you combine tyrosine kinase inhibitors with capecitabine, their response rates do seem to be much greater, and maybe as high as even 60%. So, now actually, the National Comprehensive Cancer Network has added it to their guidelines to consider the use of capecitabine and niratinib for patients who have progressive disease in the brain.

How do clinical trials provide another treatment approach for these patients?

I think clinical trials are a great opportunity for patients, because it allows them to get novel therapies before they get approved, and so it really gives them an opportunity to get a new agent that may have very promising activity, earlier than they would normally have access to it. So, usually when I’m seeing a patient, I like to always present what the standard option is so that they’re very well aware of what they could get outside of a clinical trial, but also discuss what the clinical trial option would be at that time and see what makes more sense at that particular moment, because it’s not always that the clinical trial is the right decision for them, and so it’s important to weigh the pros and cons of that approach.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!